Viscosity modulation

Viscosity modulation refers to the therapeutic alteration of the rheological properties of biological fluids, such as blood, mucus, or synovial fluid, to treat various medical conditions. It is not a single molecular target like a receptor or enzyme, but rather a pharmacological goal or physiological process achieved through diverse mechanisms (StatPearls, "Pentoxifylline"; NIH, "Mucolytics"). In vascular medicine, agents like pentoxifylline are used to decrease blood viscosity by improving erythrocyte deformability and reducing aggregation, which enhances microvascular perfusion in patients with peripheral arterial disease (PubMed, "Hemorheology and its role in red blood cell physiology"). In the respiratory tract, mucolytics such as N-acetylcysteine or dornase alfa are employed to break down the complex polymer networks in mucus—either by reducing disulfide bonds or cleaving extracellular DNA—to lower viscosity and facilitate airway clearance in cystic fibrosis or COPD (PubMed, "Mucolytic agents for chronic bronchitis or COPD"). Additionally, viscosupplementation involves the intra-articular injection of hyaluronic acid to restore the viscoelastic and lubricating properties of synovial fluid in the management of osteoarthritis (StatPearls, "Viscosupplementation"). Because this term describes a broad physical effect across multiple organ systems rather than a specific protein, it is characterized as a therapeutic mechanism or clinical outcome.

Other names

Hemorheological modulationMucolysisViscosupplementationRheological modificationBlood viscosity reduction

Modification of the physical properties (viscosity and elasticity) of biological fluids through chemical cleavage of polymeric structures, improvement of red blood cell deformability, or exogenous supplementation of viscoelastic lubricants.